Form 4: Sana Biotechnology Executive Christian Hordo Reports Stock Option Grant and Restricted Stock Units Award

Christian Hordo, EVP and Chief Business Officer of Sana Biotechnology, reports the acquisition of stock options and restricted stock units.

Summary

• Christian Hordo, EVP, Chief Business Officer of Sana Biotechnology, filed a Form 4 on March 8, 2024, reporting transactions from March 7, 2024.
• Hordo was granted 168,750 stock options with an exercise price of $9.58, expiring on March 6, 2034.
• These options vest 25% on March 7, 2025, and then in 36 equal monthly installments thereafter, contingent upon continuous service.
• Hordo also received 37,500 restricted stock units (RSUs), each representing one share of Sana common stock.
• The RSUs vest in four equal installments on March 7 of 2025, 2026, 2027, and 2028, also contingent upon continuous service.
• Following these transactions, Hordo directly owns 168,750 stock options and 37,500 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it incentivizes the executive.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules for both the options and RSUs encourage continued service and commitment to the company.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Sana Biotechnology's stock price.
• If Hordo ceases to provide continuous service to Sana, the unvested options and RSUs will be forfeited.

Future Outlook

The vesting schedules for the stock options and RSUs extend to 2034 and 2028 respectively, suggesting a long-term commitment from the executive.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard practice in the biotech industry for executive compensation.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation packages to incentivize their executives.
• The vesting schedules and grant sizes are generally comparable to industry norms for executives at similar levels within biotechnology companies.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates